Home > > > > > Report Detail

Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) - Drugs in Development, 2021

Publisher Name :
Date: 30-Apr-2021
No. of pages: 75
Inquire Before Buying

Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) - Drugs in Development, 2021

Summary

Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Secondary Progressive Multiple Sclerosis (SPMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

* This is an "on-demand" report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the Global Therapeutic Landscape of Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System).

- The report reviews pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The report covers pipeline products based on various stages of development ranging from discovery till pre-registration.

- The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities.

- The report reviews key players involved in the development of Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The report assesses Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

- The report summarizes all the dormant and discontinued pipeline projects.

- The report reviews latest news related to pipeline therapeutics for Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System).

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Identify and understand important and diverse types of therapeutics under development for Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System).

- Identify potential new clients or partners in the target demographic.

- Develop strategic initiatives by understanding the focus areas of leading companies.

- Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it's most promising pipeline therapeutics.

- Devise corrective measures for pipeline projects by understanding Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Secondary Progressive Multiple Sclerosis (SPMS) (Central Nervous System) - Drugs in Development, 2021

Table of Contents
Introduction
Global Markets Direct Report Coverage
Indication - Overview
Indication - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Indication - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indication - Companies Involved in Therapeutics Development
Company 1
Company 2
Company 3
Company XX
Indication - Drug Profiles
Drug 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug 3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug 4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug XX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Indication - Dormant Projects
Indication - Discontinued Products
Indication - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Indication, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Indication - Pipeline by Company 1, 2021
Indication - Pipeline by Company 2, 2021
Indication - Pipeline by Company 3, 2021
Indication - Pipeline by Company XX, 2021
Indication - Dormant Projects, 2021
Indication - Discontinued Products, 2021

List of Figures
Number of Products under Development for Indication, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021
  • Global CNS Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 03-Oct-2023        Price: US 3380 Onwards        Pages: 101
    Market Overview of Global CNS Therapeutics market: According to our latest research, the global CNS Therapeutics market looks promising in the next 5 years. As of 2022, the global CNS Therapeutics market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Central nervous system (CNS) disease is a widespread condition in which the brain does not function properly, limiting health and function. The......
  • Global CNS Therapeutics Market Insights, Forecast to 2029
    Published: 11-Aug-2023        Price: US 4900 Onwards        Pages: 117
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Central Nervous System Disorders Therapeutics Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application
    Published: 18-Apr-2023        Price: US 3500 Onwards        Pages: 131
    This report describes the global market size of Central Nervous System Disorders Therapeutics from 2018 to 2022 and its CAGR from 2018 to 2022, and also forecasts its market size to the end of 2028 and its CAGR from 2023 to 2028. For geography segment, regional supply, demand, major players, price is presented from 2018 to 2028. This report cover following regions: North America South America Asia & Pacific Europe MEA The key countries for ......
  • Global CNS Therapeutics Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 16-Mar-2023        Price: US 3260 Onwards        Pages: 117
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Global CNS Therapeutics Market Research Report 2023
    Published: 06-Feb-2023        Price: US 2900 Onwards        Pages: 103
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • CNS Therapeutics Market, Global Outlook and Forecast 2023-2029
    Published: 03-Feb-2023        Price: US 3250 Onwards        Pages: 100
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Global Central Nervous System Disorders Therapeutics Market Growth (Status and Outlook) 2023-2029
    Published: 02-Feb-2023        Price: US 3660 Onwards        Pages: 88
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. LPI (LP Information)' newest research report, the "Central Nervous System Disorders Therapeutics Industry Forecast" looks at past sales and reviews total world Central Nervous System Disorders Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Central Nervous System Disorder......
  • Global Central Nervous System Disorders Therapeutics Market Research Report 2023
    Published: 31-Jan-2023        Price: US 2900 Onwards        Pages: 84
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. Highlights The global Central Nervous System Disorders Therapeutics market was valued at US$ 134580 million in 2022 and is anticipated to reach US$ 169200 million by 2029, witnessing a CAGR of 3.9% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating......
  • Central Nervous System Disorders Therapeutics Market, Global Outlook and Forecast 2023-2029
    Published: 31-Jan-2023        Price: US 3250 Onwards        Pages: 69
    Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. This report aims to provide a comprehensive presentation of the global market for Central Nervous System Disorders Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and ma......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs